Abstract:Aims: We aim to explore the correlation between coronary artery calcification (CAC) score (CACS) and cardiac structure and function in chronic kidney disease (CKD) patients, create a clinical prediction model for severe CAC associated with cardiac ultrasound indexes. Methods and results: The study included 178 non-dialysis CKD patients who underwent CACS testing and collected general information, serological indices, cardiac ultrasound findings and follow-up on renal function, heart failure (HF) manifestations and re-hospitalization. The mean age of participants in the study cohort was 67.4 years; 59% were male, and 66.9% of patients had varying degrees of comorbid CAC. CKD patients with CACS > 100 were older, predominantly male and had a higher proportion of smoking, diabetes and hypertension (P < 0.05) compared with those with CACS = 0 and 0 < CACS ≤ 100, and had higher brain natriuretic peptide, serum magnesium and fibrinogen levels were also higher (P < 0.05). CACS was positively correlated with left atrial inner diameter (LAD), left ventricular end-diastolic inner diameter (LVDd), left ventricular volume at diastole (LVVd), output per beat (SV) and mitral orifice early diastolic blood flow velocity/early mitral annular diastolic myocardial motion velocity (E/e) (P < 0.05). We tested the associations between varying degrees of CAC and HF and heart valve calcification using multivariable-adjusted regression models. The risk of HF in patients with severe CAC was about 1.95 times higher than that in patients without coronary calcification, and the risk of heart valve calcification was 2.46 times higher than that in patients without coronary calcification. Heart valve calcification and HF diagnosis, LAD and LVDd are essential in predicting severe CAC. During a mean follow-up time of 18.26 ± 10.17 months, 65 (36.52%) patients had a composite renal endpoint event, of which 36 (20.22%) were admitted to renal replacement therapy. Patients with severe CAC had a higher risk of progression of renal function, re-admission due to cardiovascular and renal events and more pronounced symptoms of HF (P < 0.05). Conclusions: There is a correlation between CACS and cardiac structure and function in non-dialysis CKD patients, which may mainly involve abnormalities in left ventricular structure and cardiac diastolic function. CAC may affect renal prognosis and quality of survival in CKD patients. Based on clinical information, HF, valvular calcification status and indicators related to left ventricular hypertrophy can identify people at risk for severe CAC.

Clinical correlation between Cystatin C and cardiac remodeling in hypertension and coronary heart disease

The Impact of Serum Cystatin C on Short Term Prognosis in Petients With Ischemic Heart Failure

The Value of Cystatin C in renal Dysfunction Related to Percutaneous Coronary Intervention

Hs-cTroponins for the prediction of recurrent cardiovascular events in patients with established CHD - A comparative analysis from the KAROLA study

Association of Central Arterial Blood Pressure and Left Ventricular Hypertrophy in Patients with Chronic Kidney Disease

Cardiac Biomarkers and Left Ventricular Hypertrophy in Asymptomatic Hemodialysis Patients

Relations Between Markers of Renal Function, Coronary Risk Factors and the Occurrence and Severity of Coronary Artery Disease

Pressure overload promotes cystatin C secretion of cardiomyocytes to regulate the MAPK signaling pathway and mediate cardiac hypertrophy

Correlation Between Serum Calcineurin Activity And Left Ventricular Hypertrophy In Hypertensive Patients And Its Clinical Significance

The Ratio of NT-proBNP to CysC1.53 Predicts Heart Failure in Patients With Chronic Kidney Disease

Clinical study on relationship of hs-CRP level with presence and prognosis of cardiac dys-function in patients with type 2 diabetes after percutaneous coronary intervention

Research Progress on the Relationship between Serum Cystatin C and Heart Failure

High-Sensitivity Cardiac Troponin T Assessment to Improve Cardiovascular Risk Prognostication in Patients with Chronic Kidney Disease: Ready for Prime Time?

Association of Cystatin C Levels with Cardiovascular Risk Factors in Patients with Acute Coronary Syndrome

Predictive Value of the Serum Cystatin C/Prealbumin Ratio in Combination With NT-proBNP Levels for Long-Term Prognosis in Chronic Heart Failure Patients: A Retrospective Cohort Study

Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD

Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure

Cardiac biomarkers in chronic kidney disease are independently associated with myocardial edema and diffuse fibrosis by cardiovascular magnetic resonance

Elevated Serum Cystatin C is an Independent Predictor of Cardiovascular Events in People with Relatively Normal Renal Function

Correlation between coronary calcification and cardiac structure in non-dialysis patients with chronic kidney disease

Elevated Cystatin C Predicts Higher Mortality in Chronic Heart Failure Independently of Renal Function